CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03483103
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:24.091369+00:00
Published At: 2022-12-29T00:00:00+00:00
Record Updated At: 2023-12-20
Results Posted At: 2022-12-29
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Lymphoma, Non-Hodgkin", "Lymphoma, Nonhodgkin", "Lymphoma, B-Cell", "Lymphoma, Large B-Cell, Diffuse"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-12-20"
protocolSection.identificationModule.nctId: "NCT03483103"
protocolSection.identificationModule.officialTitle: "A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2022-12-29"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.